Skip to content

Price / book at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
Amgen logo
AmgenAMGN
20.6×-6.3×
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
5.9×+3.9×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
4.4×+2.2×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
10.3×+6.0×
TG Therapeutics logo
TG TherapeuticsTGTX
9.1×-17.0×

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%
Enterprise value$3.88B+565%
P/S1,465.1×+962×

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's price / book?
Dianthus Therapeutics (DNTH) reported price / book of 3.7× in Q1 2026.
How has Dianthus Therapeutics's price / book changed year-over-year?
Dianthus Therapeutics's price / book increased by 108.5% year-over-year, from 1.8× to 3.7×.
What is the long-term trend for Dianthus Therapeutics's price / book?
Over 3 years (2020 to 2025), Dianthus Therapeutics's price / book has grown at a 10.6% compound annual growth rate (CAGR), from 2.6× to 3.6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.